MedinCell initiates the first clinical trial of its Covid-19 prevention program
Euronext: MEDCL • Montpellier – France • September 29, 2020 – 6:30 pm CEST
First patient
was administered today The trial aims at validating the safety of continuous administration of Ivermectin in oral form
Simultaneously,
several long-acting injectable formulations based on MedinCell’s BEPO® technology
are being tested in vivo A 1-month active injectable prophylactic treatment should be ready to enter regulatory development before the end of the year
MedinCell may file for market authorization as early as 2021 Universal vaccination remains very hypothetical;
this preventive treatment should be essential in all scenarios Prophylactic sttegy
https://www.medincell.com/wp-content/uploads/2020/09/EN-PR-ivermectine_290920.pdf
France-based MedinCell Initiates Ivermectin Clinical Trial Targeting COVID-19 with Prophylactic Strategy
MedinCell
treated the first patient in a clinical trial aimed at validating the safety of continuous administration of Ivermectin in an oral form.Several long-acting injectable formulations based on MedinCell’s BEPO® technology
are simultaneously being tested in vivo.The France-based company plans for a 1-month active injectable prophylactic treatment,